Details for New Drug Application (NDA): 214723
✉ Email this page to a colleague
NDA 214723 describes HALCINONIDE, which is a drug marketed by Chartwell Rx, Mylan, and Encube, and is included in three NDAs. It is available from two suppliers. Additional details are available on the HALCINONIDE profile page.
The generic ingredient in HALCINONIDE is halcinonide. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the halcinonide profile page.
The generic ingredient in HALCINONIDE is halcinonide. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the halcinonide profile page.
Summary for 214723
| Tradename: | HALCINONIDE |
| Applicant: | Chartwell Rx |
| Ingredient: | halcinonide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 214723
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CREAM;TOPICAL | Strength | 0.1% | ||||
| Approval Date: | Sep 8, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
